Effect of anti-tuberculosis therapy on liver function of pulmonary tuberculosis patients infected with hepatitis B virus.
OBJECTIVE
To observe the effect of anti-tuberculosis therapy on liver function of pulmonary tuberculosis patients with hepatitis B virus (HBV) infection, and to compare the differences of liver function by two treatments of anti-tuberculosis.


METHODS
Forty-seven TB patients with HBV infection and 170 TB patients without HBV infection were divided into HPBE(S) and HLAMKO treatment groups. Liver function tests before and after the treatments were performed once in 2 wk or monthly, and their clinical manifestations were recorded.


RESULTS
The rate of hepatotoxicity occurred in 26 (59%) TB patients with HBV during anti-TB treatment, higher than that in 40 (24%) TB patients without HBV. Hepatotoxicity occurred in 66 out of 217 patients, and the incidence of liver dysfunction was 46.1% in HPBE(S) group, significantly higher than that in HLAMKO group (12.7%) (P<0.01).


CONCLUSIONS
TB patients with HBV should choose HLAMKO treatment because of fewer hepatotoxicity.
Pan
Lei
L
Center of Infectious Diseases, Tangdu Hospital, Fourth Military Medical University, Xi'an 710038, Shaanxi Province, China. panlei0225@sina.com
Jia
Zhan-Sheng
ZS
Chen
Lin
L
Fu
En-Qing
EQ
Li
Guang-Yu
GY
D000328:Adult; D000995:Antitubercular Agents / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D019694:Hepatitis B, Chronic / Q000150:complications* / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D008099:Liver / Q000187:drug effects* / Q000502:physiology; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D014397:Tuberculosis, Pulmonary / Q000150:complications* / Q000188:drug therapy* / Q000453:epidemiology
D000995:Antitubercular Agents